Cardiac Assist Devices Market to be Propelled by Rapidly Growing Geriatric Population

Cardiac Assist Devices (CAD) are type of mechanical pumps that work along with the heart to improve its pumping efficiency and maintain the optimum blood flow throughout the body. Cardiac Assist Devices can be segmented in three types ventricular assist devices, intra-aortic balloon pumps (IABPs) and total artificial heart. Ventricular assist device (VAD) is a mechanical pump which takes blood from a lower chamber of the heart and pumps it to the body and vital organs. Ventricular devices are of two types right ventricular assist device (RVAD), left ventricular assist device (LVAD) and if both the ventricular assist devices are used they’re known as biventricular assist device (BIVAD). Intra-aortic balloon pump is a type of CAD device which increases myocardial oxygen perfusion and cardiac output at the same time. Total artificial heart is a device which replaces the lower chambers of heart and recovers failing heart by performing all functions of a normal heart.

The rapidly growing geriatric population and the rise in cardiovascular diseases worldwide are expected to boost the growth of the global cardiac assist devices market. Dearth of donor hearts for transplantation has also fuelled the demand for cardiac assist device implantation in patients suffering from severe heart complications. During the forecast horizon, technological advancements leading to more efficient and minimally invasive devices are anticipated to drive the growth of the global cardiac assist devices market.

Current Market Structure of Cardiac Assist Devices Industries at: http://bit.ly/2eWLGoY

On the basis of the #type# of devices, the report segments the global cardiac assist devices market into right ventricular assist devices (RVAD), left ventricular assist devices, and biventricular assist devices (BIVAD). Further, intra-aortic balloon pumps and total artificial hearts are also available in the market. While intra-aortic balloon pumps increase myocardial oxygen perfusion and cardiac output at the same time, total artificial hearts replace the lower chambers of the heart. The demand for each of the types of devices has been analyzed in the report.

The report studies #the cardiac assist devices market# across North America, Europe, Asia Pacific, and Rest of the World. North America leads the overall market owing to the high number of heart failure cases diagnosed in the region, the highest of all regional segments, along with the availability of reimbursement coverage for CAD implantation procedures. Europe has emerged as the second largest region in the market. During the forecast horizon, Asia Pacific and Rest of the World are anticipated to register positive growth due to the presence of a large pool of patients suffering from cardiac diseases.

Describing the competitive landscape, the report profiles some of the key players in the global cardiac assist devices market such as ABIOMED Inc., Berlin Herat GmbH, HeartWare International Inc. MAQUET GmbH & Co. KG, Teleflex Incorporated, Thoratec Corporation, and SynCardia Systems Inc.

Sterilization: Process of Eliminating Microbiological Organisms to achieve Asepsis, Industry Trends 2019

The term sterilization refers to any procedure that helps in destroying all forms of microbial life and transmissible agents. Transmissible agents are bacteria, fungi, spore forms and virus. These micro-organisms and transmissible agents are present on the surface of medical instruments, contained in medication, fluid and biological culture media. Sterilization helps in making these culture media infection free by applying heat, pressure, chemical and filtration. This process disables the infectious protein like prions of the micro-organism and hence results in infection free medium.

Get the Forward Looking Perspective of Sterilization Industries at: http://bit.ly/2eMNLX3

Sterilization is achieved through various methods such as steam sterilization, heat sterilization, chemical sterilization, radiation and sterile filtration. In steam and heat sterilization, the artifacts which are to be sterilized are placed in a steel container and subjected to high temperature. These containers are incorporated with numerous parts that help in maintaining temperature and pressure inside the container. In chemical sterilization, various chemicals such as ethylene oxide, nitrogen dioxide, bleach, ozone, phthalaldehyde, glutaraldehyde, formaldehyde, hydrogen peroxide, peracetic acid, and silver are used. In radiation sterilization, rays like gamma, ultraviolet, electron beam and X-rays are used. These processes may sometime destroy liquid medium along with the micro-organism. To overcome this situation, sterile filtration is performed where the fluids are passed through very minute pores whose size ranges from 20 to 50 nm. These small pores do not allow the micro-organism to pass since size of these organisms is larger than the pores.

This market is expected to grow due to rise in safety processes of the various medical institution and research laboratories. In addition rise in number of surgeries and would consequently increase the demand of infection free instruments. In addition, drug preparations also require high sterile medium which would also augment the growth of this market. Moreover, the governments have made stringent rules for various medical institutes to sterile instruments after every use which would also trigger the growth of this market.

Some of the market players in this industry segment are Roche, Pfizer, Becton Dickinson, Advanced Sterilization Products, Belimed AG and bioMerieux amongst other significant players.

Hemophilia Treatment Market will Depend on its Severity and for Patients with Hemophilia A or B

The research report on the global hemophilia treatment market provides every detail that is critical in understanding the nature of the changing market dynamics. The report’s deep market analysis helps all users take informed business decisions. Distinctive and accurate graphs of a six-year forecast help create the complete picture of the global hemophilia treatment market.

Porter’s Five Force analysis, which is provided in the report, delivers an accurate competitive landscape of all the key companies in the global hemophilia market. The report also provides a SWOT analysis as well as a value chain assessment to completely cover all vital aspects of the market. It also includes a sustainability assessment for top players and new entrants alike through a complete inclusion of micro and macro industry factors.

Overview

The research report on the global hemophilia treatment market provides accurate market descriptions and statistics for the same. Hemophilia A and B are the two major areas of differentiation in the market, and a small minority of developed hemophilia, which is the rarest. Hemophilia A is an X-linked, recessive disorder, with deficiency of functional plasma clotting factor, while hemophilia B is an X-linked, recessive disorder that causes deficiency of functional plasma.

Key reasons of growth of the global hemophilia treatment market are unearthed through the growing number of research and development projects in the sector. This includes advancements in technology, research upon a series of new coagulating factors, and the introduction of new plasma and protein concentrates. There are, however, restraints that threaten to hamper the market’s growth. These include a high cost of treatment, variable availability issues in developing nations, and chemical factors such as antibody neutralization.

Read the Market Structure of Hemophilia Treatment at: http://bit.ly/2ednJsz

Between hemophilia A and hemophilia B, type A has a higher prevalence. The global hemophilia treatment market, therefore, focuses on hemophilia A. The two major regional markets for hemophilia treatment are Europe and North America. Asia Pacific is currently seen by many players as a potential market, but current high costs for the treatment are considered too much by the general public in the mostly developing countries of the region.

Both the leading regions of the global hemophilia treatment market have preferred prophylaxis treatment for severe hemophilia A nearly 40% of times. Western Europe uses prophylaxis nearly 50% of the time, while the U.S. provides it 33% of the time. The Rest of the World faces problems such as a lack of awareness and high price of treatments. Currently, one in every 5,000 newborn children is affected by hemophilia A, while one in every 30,000 is afflicted by hemophilia B.

Companies mentioned

 The top companies in the global hemophilia treatment market are Pfizer Inc., Baxter Healthcare Corp., Bayer Healthcare Pharmaceuticals, Inc., Novo Nordisk A/S, and Grifols International SA.

Gaucher Disease Drugs Market Driven with Demand for Substantial Enough Treatment for the Disease

This research report on the global Gaucher disease drugs market assesses the market depending the various market segments, overall geographical categories, and latest market trends. Our reports help you accumulate the maximum amount of data possible with the help of a precise analysis method that changes the competitive dynamics.

The report provides a complete study of all the latest market trends, growth drivers of the industry, as well as important restraints. One of the salient features of the report is an easy-to-understand pattern of data dissemination, especially in the future forecast section. The report provides a complete perspective using features like SWOT analysis and a value chain assessment. Porter’s five force model sheds light on the details of the Gaucher disease drug market. Keep yourself constantly at pace with the market by learning about its areas of growth, advantages and competitors.

Get Pin-point Analyses of Gaucher Disease Drugs Market at: http://bit.ly/2eUbgKk

Overview

Gaucher disease is a genetic and hereditary condition due to which there is a collection of fatty substances in the cells and organs. The typical symptoms of Gaucher disease include constant fatigue, anemia, bruising of skin, enlarged spleen and liver, along with low blood platelet count. The main cause of Gaucher disease is the deficiency of the enzyme glucocerebrosidase. The deficiency is hereditary, which means a child is more at risk than the adult. The enzyme acts on glucocerebroside, a glycolipid, to synthesize it. When a patient suffers from Gaucher disease, his/her glucocerebrosidase enzyme is defective, which causes a build-up of glucosylceramide, especially in the white blood cells and macrophages. The macrophages are not able to clean the fatty substance out, leading to its accumulation. The now fatty substance-filled cells are called as Gaucher Cells and look like crumpled up paper under the microscope. The fatty substance collects in the liver, spleen, kidneys, brain, lungs, and bone marrow. The signs and symptoms are varying in nature among those affected by Gaucher disease.

The key driving factor in the Gaucher disease drugs market is the growing demand for a substantial enough treatment for the disease. The disease is split into three types. Type I and type III being treatable by enzyme replacement therapy, which is a heavily expensive and a lifelong undertaking. The key restraint in fighting Gaucher disease is its rarity. The biggest reason why dose-identifying studies have been so difficult is because there have not been enough patients who suffer from the disease, to find a more optimal dosage.

Companies mentioned

 Most of the top players in the Gaucher disease drugs market are located in either Europe or North America. The key companies that are described in the research report are: Dong-A-Socio Holdings, Genzyme Corporation, ExSAR Corporation, Neuraltus Pharmaceuticals, Amicus Therapeutics, JCR Pharmaceuticals, Lixte Biotechnology Holdings, Protalix BioTherapeutics, and Greenovation Biotech GmbH.

Rising FDA Approved Botanical Drugs is a Key Opportunity for Botanical and Plant Derived Drugs Industry

Botanical drugs are drugs develop through botanical drug and research pathway, whereas plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances. These botanical products are intended for use in the mitigation, cure, diagnosis and treatment or prevention of diseases in humans.

Get the Market Growth Factors of Botanical and Plant Derived Drugs at:
http://bit.ly/2dZcwhz

The global market for botanical and plant derived drugs is witnessing a significant growth over recent years due to rising usage of these drugs in different parts of the world. Increased focus of research institutes and clinical trial studies, price reduction and improved technological and sociological development are major driving factors for the growth of this market. However, low acceptance of these drugs for the treatment of lethal diseases is a major restraint for the market. On the other hand, rising number of FDA approved botanical drugs and their application is a key opportunity for the market. Some of the major classes of botanical and plant derived drugs are Tarpenes and Steroids, Glycosides, Ergot Alkaloids, Morphine Alkaloids and Vinca Alkaloids.

Global market of botanical and plant derived drugs market is primarily divided into two segments: based on geography and based on therapeutic applications. The U.K., Germany and France are major countries of the European Region. On the basis of therapeutic application, the market is segmented into hormone related disease therapy, infectious diseases, pain and central nervous system disorders, cardiovascular and metabolic diseases, respiratory and oncology diseases treatment. Some of the major players operating in the market are Abott Laboratories, Bayer Healthcare, Bionova, Bristol Myers and Curapharm

Portable Oxygen Concentrator Market: This Technological Advanced Product can Change Lives for Better

An oxygen concentrator is a device used to deliver concentrated oxygen to a patient requiring oxygen therapy. These devices are considered as a safer, easy to use and inexpensive compared to compressed oxygen cylinders. Portable oxygen concentrator is useful to people using oxygen tanks as a constant supply of oxygen by enabling them mobility. Portable oxygen concentrator acts by increasing the concentration of oxygen by taking a mixture air from its surrounding. Airstep Freestyle, Inogen One G2, Invacare XPO2 and DeVilbiss iGo are some the commercially available portable oxygen concentrators. These devices are also used by mountaineers and people travelling to places where oxygen is inadequate amount.

Major factors expected to drive the market for portable oxygen concentrators include its ability to provide oxygen under all circumstances and worldwide aging population coupled with COPD and other respiratory diseases. Advantages associated with these devices such as they weigh less, easy to use and more affordable are also predicted to drive the market further. WHO suggests that approximately 65 million people are suffering from moderate to severe chronic obstructive pulmonary disease across the globe. In 2005, an estimated 3 million people died because of COPD. North America and Europe are the market leaders because of high level of consumer awareness and approval by regulatory authorizes of these regions. FAA (Federal aviation Administration) approved the onboard use of certain portable oxygen concentrator. In Asia-Pacific, Japan, India, China and Australia are the leaders in the market for portable oxygen concentrators. In Latin America, Mexico and Brazil are expected to witness a substantial growth in coming years due to continuously increasing healthcare expenditure in the region.

Perceive the Commercial Extensive Data of Portable Oxygen Concentrators at:

http://bit.ly/2eFamlD

Some of the major companies operating in this market are Inogen, Philips Healthcare, AirSep, O2Concepts Oxlife, Vygon, Nidek Medical, Inova Labs, OSI Systems, Smiths Medical and Teijin.

Digital Health Market: Converging Digital and Genomic Revolutions with Health and Society

Digital health is technology-enabled care that involves the convergence of digital media, health technology, and mobile devices. It is designed to help patients, care givers, and healthcare professionals access relevant data easily and improve the quality of both social and health care. Digital health is gaining impetus since it provides cost-effective solutions at a time when the demand for healthcare services is persistently increasing.

The rising aging population, increasing price of advanced treatments, and shrinking healthcare expenses by governments have impelled healthcare providers to look for complementing solutions to sustain future social and health care systems. Opportunities for deploying mobile technology in a healthcare set-up have significantly increased in the last few years. The proliferation of smart devices and smartphones has played a crucial role in propagating digital health. Notable developments in bio-sensing wearables such as glucose, blood pressure, and diabetes monitors are further expected to augment the interest in digital health.

Digital health enables access to real-time health care data. Furthermore smartphones and wearable medical devices integrating an increasing range of sensors to facilitate monitoring changes in physiology. Therefore, the applicability of digital health is expected to surge extraordinarily in the near future.

Digital health refers to a system or solution that delivers effective health care solutions using IT tools and products. It is possible to provide better and more efficient care compared to traditional healthcare via patient online services and digital diagnostic techniques. Latest digital health technologies such as electronic health records (EHR), wireless technologies, and digital diagnostic systems encompass data such as patient history, medication, allergies, immunization dates, radiology images, diagnosis, laboratory and tests results, treatment plans, and insurance information.

Attain the Technological Breakthroughs of Digital Health Industries at: http://bit.ly/2dHhm4l

The global digital health market is exhibiting robust growth due to the increasing demand for advanced information systems in the health care industry. Favorable policies by governments and the rising investment by players in the healthcare information system (HIT) have also been aiding the expansion of the digital health market. Additionally, the market is also gaining impetus from the growing demand for remote monitoring services in response to the proliferation of home healthcare services.

On the flip side, certain restraints often associated with the global digital health market include high capital expenditure, privacy and security issues, expenditure incurred on maintenance requirement, and inadequate infrastructure of the healthcare industry in developing countries.

Regionally, North America dominates the global digital health market and is expected to maintain its dominance through the forecast period. This exponential surge witnessed by the regional market is aided by the developed healthcare infrastructure, increased healthcare spending, and the increasing incidence of chronic illnesses in the region.

The digital health market is also witnessing attractive opportunities in Europe. The European market is primarily aided by the increasing geriatric population, rising prevalence of chronic ailments, and technological advancements introduced in the HIT. However, during the forecast period, the Asia Pacific digital health market is expected to report growth at highest rate. The increasing investment in healthcare and IT will support the growth of the digital health market in Asia Pacific.

To present insights into the competition prevailing in the market, the report also profiles companies such as General Electric Company, AT&T Inc., McKesson Corporation, Cisco Systems Inc., and others.

Antibody Drug Conjugates Market Driven by Extensive Research and Development Activities

Antibody drug conjugates are monoclonal antibodies that are attached with biologically active drugs. The combination of cytotoxic drugs and the targeting capacity of molecular antibodies allows antibody drug conjugates to perform targeted therapy to treat cancer patients. This allows a sensitive discrimination between cancerous tissues and healthy tissues. As the global antibody drug conjugates market is in an infancy stage, only three antibody drug conjugates have received market approval from the United States Food and Drug Administration (FDA).

The first among the three, Mylotarg, was withdrawn from the global market by its manufacturer, Wyeth, Inc., a company of Pfizer, Inc., in June 2010. Mylotarg was primarily used for treating acute myelogenous leukemia. Thus, by drug, the global antibody drug conjugates market is now classified into Kadcyla and Adcertis.

Adcertis (Brentuximab vedotin) is a special antibody drug conjugate that is directed towards the CD30 protein and is expressed in systemic anaplastic large cell lymphoma and Hodgkin lymphoma. Seattle Genetics, in Feb 2011, submitted a Biologics License Application to the United States FDA for use in refractory Hodgkin lymphoma and relapsed anaplastic large cell lymphoma. The drug received accelerated approval from the United States FDA in August 2011. Adcertis led the global antibody drug conjugates market during the period between August 2011 and February 2013. In October 2012, Adcertis received marketing authorization from the European Medicines Agency.

Get Future Perspective of Antibody Drug Conjugates Industry at: http://bit.ly/2eALBv7

Kadcyla (Trastuzumab emtansine) is an antibody drug conjugate that consists of the monoclonal antibody trastuzumab and is linked to cytotoxic agent mertansine DM1. In Italy, clinical trials on women suffering from HER2 positive breast cancer showed that Kadcyla improved their survival by 5.8 months. Due to this, Kadcyla received approval from the United States FDA in February 2013. Kadcyla, developed by Genentech, Inc., a subsidiary of F. Hoffmann-La Roche AG, is manufactured by Lonza group. The introduction of Kadcyla boosted the growth of the global antibody drug conjugates market during the period between 2012 and 2013.

By geography, the global antibody drug conjugates market is divided into Asia Pacific, North America, Europe, and Rest of the World. Most antibody drug conjugates in the development phase are for oncological indications and are propelled by the easy availability of monoclonal antibodies that target various types of cancer. At present, leading players in the global antibody drug conjugates market are targeting different domains other than oncology to develop antibody drug conjugates.

The high cost involved in the research and development activities to discover new antibody drugs is expected to restrict the growth of the global antibody drug conjugates market in the years to come. Biotest Pharmaceuticals Corporation, Synthon BV, Bayer AG, and Immunomedics, Inc. are some of the leading companies in the global antibody drug conjugates market.

Pneumonia Diagnostics & Technologies Market – Evaluating New Diagnostic Technologies

Pneumonia is a type of lung infection caused by microorganisms such as bacteria, virus, fungi and parasites. Streptococcus pneumonia is one of the most common causes of pneumonia among children, others are Haemophilus influenzae type b (Hob) and Pneumocystis jiroveci. It is characterized by symptoms such as short breathing, fever, chest pain, nausea and vomiting. In pneumonia the air sacs of lungs called as alveoli are filled with fluid or pus that causes inflammation. The treatment of pneumonia depends on severity of symptom and types of pathogens. Usually, antibiotics are given to treat pneumonia caused by bacterial infection while to treat pneumonia caused by fungi, antifungals are prescribed.

Current Industrial Trends of Pneumonia Diagnostics & Technologies: http://bit.ly/2eErhX2

It is quite difficult to diagnose pneumonia as its clinical symptoms overlap with many other diseases such as the asthama, bronchitis and common cold. In order to confirm pneumonia, a doctor recommends tests including chest X-ray, blood tests, sputum test, CT scan, pleural fluid culture and pulse oximetry test. The market for pneumonia diagnostics and technologies can be estimated on the basis of volume of tests generated at hospitals, diagnostic laboratories, physician’s own clinics and other healthcare settings. Chest x-ray and CT scan are generally recommended at hospitals for the diagnosis of pneumonia while community healthcare settings usually recommend diagnosis on the basis of symptoms. Some of the key players operating in this market space are Becton Dickinson, Affymetrix, Bio-Rad, Abbott Laboratories, Roche, Thermo Fisher Scientific, bioMeriux, DiaSorin and Novartis Diagnostics. Some of the diagnostic kits available in the market are Directigen S. pneumonia test kit by Becton Dickinson and LCx Chlamydia pneumonia PCR assay kit by Abbott Laboratories.

The market for pneumonia diagnostics and technologies is projected to grow under the influence of increasing aging population, recent advances in pneumonia diagnostics and high prevalence of pneumonia among children. Rapid increase in aging population in North America, Europe and Japan will be driving the market in these regions as elder people are more susceptible to develop pneumonia compared to general population. As of April 2013, WHO (world health organization) suggests that pneumonia is one of the major factors causing death in children. It is estimated that every year approximately 1.2 million children under the age of five years die due to pneumonia. This disease is most prevalent in South Asia and African countries. The recent advancement in pneumonia diagnostics such as the development of nucleic acid detection tests for major pneumonia pathogens and immunochromatographic pneumococcal urinary antigen tests are predicted to drive the market globally.

Industrial Enzymes Market is Growing with Increasing Demand for Bio Fuel

Industrial enzymes are molecules or complex proteins that help in catalysis of biochemical reactions. Industrial enzymes have the characteristics of reducing the energy consumption of a reaction without being consumed in the reaction. On the basis of product type, industrial enzymes market can be segmented as lipase, carbohydrase and protease. On the basis of its applications, industrial enzymes market is segmented into four segments including food & beverages, bio fuel, cleaning agents and other applications including animal feed. Food & beverages is the most dominant application segment for industrial enzymes and this trend is anticipated to continue for a foreseeable future.

Enzymes are produced by living cells and industrial enzymes market can be segregated into three segments on the basis of the source namely microorganisms, animals and plants. Fermentation is the most dominant process used for the production of industrial enzymes. Microorganisms such as yeast and bacteria among others are employed in the fermentation process. Solid state fermentation and submerged fermentation are dominant fermentation process used in enzymes production. Submerged fermentation involves a liquid medium for enzyme production and solid state fermentation employs a solid substrate for the production. Centrifugation or lysing process is used for extraction of enzymes produced extracellularly or intracellularly by the microorganism.

Major portion of the global production of industrial enzymes is employed in the production of food & beverages including cheese, bread and alcohol among several others. Increasing demand for packaged food & beverages have led to high growth in food & beverages application segment that has been among foremost factors driving demand for industrial enzymes. There has been a surge in government incentives and benefits to promote the use of bio fuel as a substitute for the conventional non renewable sources of energy. Increasing demand for bio fuel primarily driven by the surge in government incentives and the environmental benefits associated with bio fuel is anticipated to be among major factors driving demand for industrial enzymes in the near future. Research and development activities to increase the application scope of industrial enzymes are anticipated to offer huge growth opportunity for market growth.

Get Forward Looking Perspective for Industrial Enzymes at: http://bit.ly/2dCj4E2

North America followed by Europe dominates the global demand for industrial enzymes. Moreover, market shares of North America and Europe are anticipated to decline in the near future primarily owing to relatively high growth in Asia Pacific and RoW region. Increasing demand for bio fuel is expected to be foremost factors driving demand for industrial enzymes in North America and Europe. Asia Pacific is the third largest market for industrial enzymes. Moreover, Asia Pacific comprises two of the largest countries in terms of population, India and China leading to huge demand for food & beverages in the region. Furthermore, high GDP growth and increasing disposable income in the emerging economies of Asia Pacific is expected to drive demand for industrial enzymes in the region. Owing to aforementioned factors, Asia Pacific is anticipated to be the fastest growing geographic segment for industrial enzymes during the forecast period. High growth in developing economies of South America and Africa are anticipated to offer huge growth opportunity for industrial enzymes in the near future.

Some of the key players in industrial enzymes market include Amano Enzyme Inc., Novozymes, BASF SE, Dyadic International Inc., E. I. du Pont de Nemours and Company, Codexis Inc. and The Soufflet Group among others.

Home Healthcare Market to Gain Impetus from Rising Base of Geriatric Population

A new study by Transparency Market Research (TMR), titled “Home Health Care Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024,” states that the increasing base of geriatric population and the rising incidence of chronic diseases are boosting the market significantly.

In addition to this, the emergent technical advancements in the field of home healthcare and the growing demand for highly effective yet cost-efficient healthcare delivery systems are expected to propel this market during the forecast period. However, the rising concerns over patients’ safety, consistent changes in reimbursement policies, and insufficient insurance coverage options are likely to hamper the growth of this market in the coming years, notes the research study.

The report studies the global home healthcare market on the basis of the product, service, delivery mode, and the region. Based on product, the market has been categorized into mobility care products, testing, monitoring, and screening products, and therapeutic products. Among these, the demand for testing, monitoring, and screening products is rising significantly.

Further, the study has classified the mobility care products segment into cranes, crutches, walkers, mobility scooters, and wheelchairs. The testing, monitoring, and screening products segment has been classified into heart monitoring systems, peak flow meters, blood pressure monitors, pulse oximeters, HIV test kits, and ovulation and pregnancy kits. Oxygen delivery systems, ventilators, nebulizers, wound care products, inhalers, insulin delivery devices, and dialysis devices have been identified as the main therapeutic products available in the home healthcare market.

Get the Complete Market Structure of Home Health Care at: http://bit.ly/2eyHyep

Based on service, the report has segmented the worldwide home healthcare market into rehabilitation services, infusion therapy services, unskilled care services, respiratory therapy services, pregnancy care services, skilled care services, and palliative care and hospice. The infusion services segment is likely to gain significant impetus from the increasing demand for these services over the forecast period.

By delivery mode, the market has been categorized into cloud-based home healthcare, web-based home healthcare, and on-premise home healthcare. Among these, the cloud-based segment is projected to dominate the global market over the forecast period.

Region-wise, the report has segmented the global market for home healthcare into North America, Asia Pacific, Europe, and the Rest of the World.

A&D Co. Ltd., Apria Healthcare Group Inc., Almost Family Inc., Abbott Laboratories, Amedisys Inc., Fresenius Se & Co. KGaA, General Electric Co., Kindred Healthcare Inc., Kinnser Software Inc., LHC Group Inc., Linde Group, Mckesson Corp., Omron Corp., Philips Healthcare, and Roche are some of the key players operating in the home healthcare market, states the research report.

Hospice Market is Increasing due to Increasing Prevalence of Diseases Among Growing Aging Population

Hospice center is referred to as the place that provides end-of-life care to patients. At hospice, a team of health care professionals and volunteers provide care that focuses on palliation of seriously ill patients. They provide psychological, spiritual and medical support to the patient. The aim of hospice is to help diseased patients, who have less period of life span remaining, to have comfort, peace and dignity. Usually, patients to whom hospice services are provided are predicted to survive six months or even less than that. The caregivers try to cure pain and other symptoms so that patients can remain comfortable and alert as long as possible. Besides, hospice services also provide help and support to patient’s family. According to the place of providing these hospice services, hospice market is divided into four major segments:

> Home hospice care

> Hospice center

> Hospital

> Skilled nursing facility

Among all of the above mentioned places, hospice centers followed by home hospice care are preferred by patients. Hospice centers are preferred because it provides a friendly environment to the patients where one does not feel lonely mainly due to the presence and accompany of similar patients. These centers also provide mental support to the patients through certain special activities such as meditation, spiritual speeches and parties.

The hospice market is increasing at faster pace majorly due to the increasing prevalence of the diseases among the growing aging population worldwide. According to the data of Centers for Disease Control and Prevention (CDS), in 2010 there were 40 million people who aged 65 and above in United States accounting for 13% of the total population and CDC projected that around 20% of the population of U.S. would be under this category by 2030. Additionally, availability of large number of diverse programs according to the disease condition and economic condition of the patient is also helping the market to grow. According to the disease conditions special programs are designed by hospice providers on the basis of cancer, AIDS, heart diseases, kidney failures, liver diseases and many others.

Get the Pin-Point Analysis of Hospice Market: http://bit.ly/2eJqUJx

North America and Europe leads the global hospice market majorly due to the extensive support from the government to set up the infrastructure and other essential necessities required by hospice centers. Hospice care expenses in U.S. are mostly paid by the Medicare and Medicaid services and Department of Veterans Affairs. Additionally, most of the private insurance plans, health maintenance organizations (HMOs) and other managed care organizations also provide the expenses for hospice care in their plans and policies. Also, large number of community contributions, foundation gifts and memorial donations in U.S. are helping hospice market to give free services to poor patients. Asia-Pacific is currently at growth stages for hospice market and has set up few hospice centers with the help of government, private sectors and renowned doctors. For instance, Dr. L. J. Desouza, a cancer surgeon, has set up hospice centers in Mumbai, Goa and Delhi with the name Shanti Avedna Sadan. This center is focused on providing treatment for cancer patients. The countries which are majorly driving the hospice market in Asia-Pacific region include India, China, Japan and Taiwan.

Some of the market players in hospice market include AMEDISYS, Inc, Gentiva Health Services, LHC group, Almost Family, HCR Manor Care, Seasons Hospice and Pallative Care, AseraCare Hospice, Compassionate Care Hospice, Crossroads Hospice and Accent Care, Inc.

Combined Angiography Systems with DSA and CT Scan to Treat and Diagnose Blood Vessel Abnormalities

Angiography is an X-ray imaging technique in which, contrasting agents are injected into the blood stream to visualize the blood vessels and help understand the abnormalities of blood vessels such as aneurysms and atherosclerosis. It is commonly used for diagnosing the heart diseases such as Coronary artery diseases. According to WHO, in 2012, 17.2 million people have died from cardiovascular diseases globally. Among them, 42.2% of the population were victims of the coronary artery disease. Computed Tomography (CT), angiography, and Magnetic Resonance Imaging (MRI) angiography are new angiography techniques that are used to diagnose abnormalities in blood vessels. These procedures are heal comparatively faster than conventional X-ray angiography technique (digital subtraction angiography). However, in this procedure, only abnormalities in blood vessels are diagnosed whereas conventional angiography helps in diagnosing abnormalities and treating blocked arteries.

Hence, in recent years angiographic imaging system vendors have developed combined angiography device systems, which have both DSA and CT scan to treat and diagnose the blood vessel abnormalities. These devices are present in two different operating rooms to diagnose and treat the blood vessel diseases due to which, most of the time is often lost in transferring the patients from the CT room (Diagnosis) to angio room (Treatment). Hence, combined angiography system plays an important role in treating and diagnosing the patient in same operating room and reduces space for the equipment.

These systems have a new 3D-application which links the angiography systems with CT images previously taken during the interventional process. Hence, the systems provide exceptional imaging qualities and makes it easier for surgeons to conduct surgeries. Few companies have developed mobile platforms to enable the multidisciplinary teams perform the procedures comfortably without any obligatory access to patients. In addition to these, systems will provide precision dosing, which expose the patient to less radiation as compared with the conventional system.

These systems have multiple-utility application areas, rising incidence of cardiac diseases, adaptation to new technologies and increasing awareness about the disease are the major factors driving the growth of combined angiography market. Complex regulatory process and the high cost of these systems are limiting factors for the combined angiography system market in the forecast period.

Perceive Key Competition Landscape of Combined Angiography: http://bit.ly/2dFigNd

These new angiography systems are expected to boost the market growth during the forecast period. The angiography system will have both X-ray and CT scan which enables the doctor to choose appropriate scan to diagnose the disease. Furthermore these devices help in delivering of precision dose and surgeries can be performed in the single operating room. In addition to that, these systems can provide 3D/4D image visualization during the surgery process.

The product type is segmented into five categories - Discovery IGS system, MIYABI Angio-CT, Trinias series MiX Package, INFX-8000C + CT (Aquilion), and Allura Clarity. GE Health Care, Discovery IGS system, is expected to have a large market share in USA because it recently got FDA approval in USA.

Based on the application type, the segment is categorized into Heart, Brain, Renal, and Other diseases. Among them, cardiac segment is expected to hold a major share due to their well-known utility of these systems in the cardiac area and increase in cardiac diseases.

Based on the End User, it is segmented into Hospitals, Diagnostic, and Research centers. Among them Hospitals segment is expected to hold a major share due to the systems that serve dual purpose of conducting surgeries as well as diagnosis of abnormalities.

On the basis of geographical segmentation, the angiography system is segmented into five key regions- North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America is expected to hold the largest market share followed by Europe. However, APAC market is expected to grow during the forecast period due to factors such as increase in the incidence of diseases, rise in awareness, improving health care facilities.

The key players in this market are Siemens Health Care, GE Health Care, Shimadzu, Toshiba, Philips healthcare, and Omega. In this angiography segment, the market is expected to be dominated by major players owing to high investments for the development of these systems.

Care Management Solutions have Redefined Patient-Centric Care in more Ways than One

Global Care Management Solutions Market: Overview

Factors such as the explosion of big data, an undeniable shift toward patient-centric care, and the rising need to streamline expenses are all coming together to act as enablers for the growth of the global care management solutions market. Care management solutions and software enables healthcare providers to manage data pertaining to their members. It also helps healthcare providers to make better decisions and meet their goals faster by offering population management solutions to keep a check on costs without compromising on quality.

A typical care management solution first accesses the data of a patient to assess their healthcare needs. Care management software then provides healthcare plans and brings various coordinators on the same page so different departments can seamlessly execute the task at hand. Some care management solutions are also integrated with transplant networks or other healthcare establishments. By creating an all-encompassing platform where the healthcare providers, the patient, and their family can track and monitor the status of healthcare programs, care management solutions have redefined patient-centric care in more ways than one.

The global care management solutions market has thus seen the emergence of several vendors, many of whom are large companies with diversified business interests. The report analyzes the factors that are driving more care managers across the world to make investments in care management solutions. It also takes a look at the factors that will restrain growth and updates readers about the latest trends emerging in this space.

Global Care Management Solutions Market: Drivers and Restraints

The biggest driver arguably for the rapid development of the global care management solutions market is the healthcare-associated risk shifting from the patients to the healthcare providers. With patient-centric healthcare policies having transformed the way medical care is delivered, it is now easy to see why the demand for care management solutions and software in rising steadily. Where until a few years ago manual processes were the only means of carrying out everyday operations, automation and interconnectivity have made that approach nearly obsolete.

Bring out the Emerging Niche Segments for Care Management Solutions Industry at:

http://bit.ly/2ecwTrU

At the same time, the global medical tourism industry is registering impressive growth numbers year on year. This has helped healthcare establishments in emerging economies adopt a positive investment sentiment as far as care management solutions are concerned. Another high-impact growth driver for the global care management software and solutions market is the massive data that virtually every medium and large healthcare organization generates. Organizations endeavoring to make the most of this data are now more willing to use care management solutions as a means.

However, it would be too early to say that the growth of the care management solutions market has taken off in the real sense. Several regions that have high investment potential but are hamstrung by the lack of internet connectivity are a missed opportunity for companies in the global care management solutions market. Moreover, in some countries in Asia and Latin America where basic healthcare infrastructure still remains below the desired levels, it will be a while before the environment becomes conducive to the adoption of care management solutions and software.

Global Care Management Solutions: Opportunities

The demand for chronic care management solutions is where most companies are currently finding lucrative opportunities. Chronic diseases account for well over half of all deaths worldwide. With chronic diseases such as cancer, diabetes, stroke, cardiovascular disease, and respiratory diseases assuming epidemic proportions, hospitals are finding themselves faced with certain challenges – many of which can be taken head on with the use of care management solutions.

Thus, the use of care management solutions for chronic conditions will continue to remain a massive revenue generator for the market.

 Companies that currently stake a claim to the highest revenue shares in the global care management solutions market are: TriZetto Corporation, Allscripts Healthcare Solutions, Inc., EXL Healthcare (U.S.), HealthSmart Holdings, Inc., and others.

Telehealth Encompasses Variety of Technologies and Tactics to Deliver Virtual Medical Services

The modern world is shifting from conventional medical treatment to technologically advanced equipped treatment services. The concept of telehealth services was conceived with the idea of exchanging data remotely between a patient at home and a doctor. Telehealth services include diagnosis and monitoring of patients, generally those with long term ailments. Telehealth includes fixed or mobile home units, which measure clinical parameters such as blood pressure, sugar level, body temperature, and others, using a wireless medium.

The global telehealth services market is growing owing to the rising adoption of these services by a large number of people suffering from long term ailments. Patients are opting for telehealth services as they reduce the number of doctor visits, thus saving both time and money. Telehealth services have helped reduce the mortality rate and the incidences of emergency admission to some extent. Today, telehealth is being used for disaster management, dentistry, consumer and professional education, counselling, and physical and occupational therapy, thus boosting the telehealth services market. However, the high installation cost of telehealth systems may hamper the growth of the global telehealth services market.

Get the Complete Information on Telehealth Services at: https://goo.gl/lP3gFw

The global telehealth services market is segmented on the basis of end user, type, application, and geography. Clinical and non-clinical are sub-segments of the type segment. Clinical uses comprise diagnosis of disease, disease management, advice on prevention from diseases, promoting good health, and using telephonic medium to deal with emergency situations. Non-clinical uses of telehealth services include distance education, movement of patient and remote admission, research programs on telehealth services, health data management, and providing online information.

On the basis of application, the market is segmented into dermatology, cardiology, gynecology, neurology, and orthopedics. The global telehealth services market is segmented on the basis of end user into telehome, telehospital, assisted living, worried well living, and facility. On the basis of geography, the telehealth services market is segmented into Latin America, North America, Asia Pacific, Europe, and Rest of the World.

Key players operating in the global telehealth services market, which have been included in the report for the purpose of study are: LifeWatch AG, Allscripts Healthcare Solutions, Inc., McKesson Corporation, CARDIOCOM, LLC, Polycom, Inc., F. Hoffmann-La Roche Ltd., AMD Global Telemedicine, Inc., Cisco Systems, InTouch Technologies, Inc., Philips Healthcare and Honeywell HomMed LLC.

Patient Safety Coupled with Technological Advancement is Driving the Use of Medical Simulation

Medical Simulation is a branch of science technology which is used to educate and train the medical professionals about surgeries, prescriptions and general surgeries. These are also used to train students in anatomy and physiology during their clinical trainings. The end users of the medical simulation technology markets are academics, military, hospitals and others.

According to the Institute of Medicine, around 44,000 to 98,000 deaths occur annually worldwide due to medical errors during patient treatment. To reduce these errors medical simulation is used extensively as it increases the patient’s safety. Patient safety coupled with technological advancement is driving the use of medical simulation. Other factors which propel the growth include increase in health care cost and rise in demand of minimal invasive treatments. High cost of simulators is persists to be an obstacle for the growth of this market along with availability of fewer funds.

Forecasting the Various Key Product Segments of Healthcare/Medical Simulation at:

https://goo.gl/6N20Zs

Medical Simulation uses the haptic and virtual and reality technology. Haptic technology works on the senses of touch by applying forces, vibration and the motions and assists in realistic, multisensory learning to the medical students and healthcare professionals while virtual and reality technology uses computer simulated environment to simulate the physical presence in both, the real world as well as imaginative world . It helps surgeons to learn surgery without actual use of patients. This thus reduces the risks of patients and also helps to train the surgeons for new surgical procedures Products and services of simulation markets includes Computed Tomography, Magnetic Resonance Imaging, high fidelity mannequins, live environments, simulated clinical environment, serious game, Positron Emission Tomography, fidelity trainers, performance recording, imaging simulation, IV simulators, second life, interventional simulators, cardiovascular simulators, mid/low simulator, ultrasound imaging, surgical simulators and healthcare/medical simulation training services. Largest market for the healthcare/medical simulation is North America followed by Europe and Asian region. China and India are expected to be the booming market for the same industry in near future.

Some of the major players in the healthcare/medical simulation market include B-Line Medical, LLC, 3B Scientific GmbH, CAE Ltd., Anesoft Corporation and others.

Increased Cyber-Attack Threat makes a Solid Hike in Healthcare Cyber Security Industries

Cybersecurity technologies are fast evolving across the globe owing to the changing digital landscape, where security threats are becoming more damaging and smarter. Today, amid the connected health environment, cyber security is not an option, rather it is a compulsion. For every organization, cyber security has become a strategic asset. The healthcare industry is increasingly implementing healthcare IT infrastructure to easily access, send, receive, and manage health care data. The rise in the patent violation cases, medical identity frauds, loss of patient information, and business record breaches are predicted to propel the global healthcare cyber security market in the years to come.

Get the Outlook for the Industries of Healthcare Cyber Security:

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11078

The global healthcare cyber security market is segmented on the basis of end user, region, and solution type. By region, the global healthcare cyber security market is divided into North America, Europe, Asia Pacific, and Rest of the World. Currently, North America dominates the global healthcare cyber security market owing to the increasing presence of a developed medical and healthcare infrastructure. Going forward, factors such as the increasing spending on healthcare information technology, the availability of medical and pharmaceutical devices, and the rising government support are expected to propel the North America healthcare cyber security market.

Asia Pacific is expected to be the attractive market in the years to come owing to economic developments in nations such as India, Japan, and China. Further, the Asia Pacific healthcare cyber security market is expected to grow swiftly due to the rapid enhancements in the healthcare sector. Developing a technically advanced cyber-system platform is a necessity today. Leading players such as Cisco Systems, Inc., MacAfee, Inc., Symantec Corporation, IBM Corporation, Palo Alto Networks, Inc., Lockheed Martin Corporation, Northrop Grumma Corporation, FireEye, Inc., and Kaspersky Lab are taking efforts to introduce new healthcare cyber security platforms in the global market.

By solution type, the global healthcare cyber security market is classified into identity and access management, intrusion detection system, risk and compliance management, antivirus, data encryption software, antimalware, firewall, and others. Currently, the global healthcare cyber security market is dominated by the identity and access management segment. Based on end user, the global healthcare cyber security market is classified into medical devices companies, pharmaceutical and chemical manufacturers, hospitals, and health insurance companies.

Healthcare Cyber Security Market Description:

http://www.transparencymarketresearch.com/healthcare-cyber-security-market.html

Companies Target Better Clinical Trial Outcomes a Benefit for Computational Biology Industry

The computational biology market is predicted to have a notable growth owing to its wide use by biotechnology and pharmaceutical companies to reduce the incidences of late stage failures of their drugs and thereby curb R&D expenditure. This market involves application of biology and information technology field for drug discovery and drug development. Computational biology also assists in reducing extensive use of human in clinical trials and is therefore useful for pediatric trials, trials on pregnant women and orphan disease research. The computational biology market has witnessed significant growth in the past due to rise in late stage drug failure coupled with its ability to reduce extensive use of humans in clinical trials.

Get Computational Biology Industrial Outlook:

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1120

This report provides an in-depth and comprehensive analysis of the computational biology market on the basis of application, tools and by services. This report studies the global market for computational biology through the perspective of cellular modeling and disease modeling. In application segment, the report covers cellular & biological simulation and disease modeling and simulation application or CADD (Computer Aided Drug Design). Cellular & biological simulation market has also been segmented on the basis of computational genomics, computational proteomics, pharmacogenomics and others (transcriptomics/ metabolomics). Disease modeling and simulation segment is categorized into drug discovery and drug development. The market of drug discovery is divided into target identification, target validation, lead discovery and lead optimization. Drug development market is segmented as preclinical, clinical trials and human body simulation software. The market of clinical trials is studies based on phase I, phase II and phase III trials.

The market of computational biology market, by tools is categorized into database, IT infrastructure (hardware) and analysis software and services types. The computational biology services market highlights the trend of in-house computational biology and external or contract computational biology. The report also provides various types of technological advancements taking place in each segment. All the above mentioned segments are analyzed on the basis of market size in terms of USD million and their forecasts for the period 2012 to 2018 have also been provided. The CAGR (%) for each market segment has been estimated for the forecast period 2012 to 2018, considering 2011 as the base year. In addition, this report covers participation of different organizations of the U.S. and the U.K. for the development of computational biology market.

Computational Biology Market Description:

http://www.transparencymarketresearch.com/computational-biology.html

The market is also forecasted in terms of value (USD million) for the period 2012 – 2018 for four major geographic regions, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). Market sizes, forecasts and % CAGR for each region have been provided in geography segment. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the computational biology market and future opportunities are covered in the report. Moreover, a PESTLE analysis has been done while estimating individual geographies in order to provide current as well as future status. A list of recommendations for existing as well as new entrants has been discussed in the study. This recommendation chapter provides assistance to industry players on ways to enter this market or to establish sustainable competitive advantage.

Some of the key market players of the global computational biology market include Genedata AG, Nimbus Discovery LLC, Rhenovia Pharma SAS, Certara, Chemical Computing Group, Inc., Compugen, Ltd, Simulation Plus, Inc., Schrodinger, Leadscope, Inc., Accelrys, Entelos and Insilico Biotechnology AG. Market players are profiled in this report on the basis of attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits, product portfolio and recent developments. The competitive landscape of this industry has been covered under market share analysis by key players.